{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:56:18Z","timestamp":1784724978886,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jpba.2019.03.065","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T16:35:02Z","timestamp":1554482102000},"page":"104-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["A clinical study for the evaluation of pharmacokinetic interaction between daclatasvir and fluoxetine"],"prefix":"10.1016","volume":"171","author":[{"given":"Mohamed","family":"Oraby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Khorshed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Abdul-Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramadan","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed M","family":"Elsutohy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jpba.2019.03.065_bib0005","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1478-3231.2009.02204.x","article-title":"Is the hepatitis C virus epidemic over in Egypt? Incidence and risk factors of new hepatitis C virus infections","volume":"30","author":"Mostafa","year":"2010","journal-title":"Liver Int."},{"issue":"9","key":"10.1016\/j.jpba.2019.03.065_bib0010","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","article-title":"Epidemiology and natural history of HCV infection","volume":"10","author":"Hajarizadeh","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.jpba.2019.03.065_bib0015","first-page":"251","article-title":"Somatic symptoms and the association between hepatitis C infection and depression in HIV-infected patients","volume":"58","author":"Yoon","year":"2010","journal-title":"J. Investig. Med."},{"issue":"8","key":"10.1016\/j.jpba.2019.03.065_bib0020","doi-asserted-by":"crossref","first-page":"18033","DOI":"10.3390\/ijms160818033","article-title":"Hepatitis C in special patient cohorts: new opportunities in decompensated liver cirrhosis, end-stage renal disease and transplant medicine","volume":"16","author":"Husing","year":"2015","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.jpba.2019.03.065_bib0025","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.14309\/00000434-200609001-00371","article-title":"Psychiatric and substance use disorders are associated with increased mortality among US veterans with hepatitis C infection","volume":"101","author":"Rifai","year":"2006","journal-title":"Am. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.jpba.2019.03.065_bib0030","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/jurban\/jth114","article-title":"Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the beck depression inventory","volume":"81","author":"Golub","year":"2004","journal-title":"J. Urban Health"},{"issue":"4","key":"10.1016\/j.jpba.2019.03.065_bib0035","first-page":"336","article-title":"Efficacy and safety of daclatasvir in hepatitis C: an overview","volume":"4","author":"Gamal","year":"2016","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"2","key":"10.1016\/j.jpba.2019.03.065_bib0040","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","author":"Liver","year":"2018","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.jpba.2019.03.065_bib0045","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2012.10.027","article-title":"Clinical management of drug-drug interactions in HCV therapy: challenges and solutions","volume":"58","author":"Burger","year":"2013","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.jpba.2019.03.065_bib0050","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s40262-016-0407-2","article-title":"Drug-drug interactions between direct-acting antivirals and psychoactive medications","volume":"55","author":"Smolders","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2019.03.065_bib0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jpba.2016.05.016","article-title":"Development and validation of sensitive and rapid UPLC-MS\/MS method for quantitative determination of daclatasvir in human plasma: application to a bioequivalence study","volume":"128","author":"Rezk","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.03.065_bib0060","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jchromb.2017.12.018","article-title":"UPLC-MS\/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV\/HCV co-infected patients","volume":"1073","author":"Notari","year":"2018","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2019.03.065_bib0065","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jpba.2015.01.027","article-title":"Multiplexed LC-MS\/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma","volume":"107","author":"Jiang","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.03.065_bib0070","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jpba.2016.11.032","article-title":"Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasma","volume":"134","author":"Nannetti","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.03.065_bib0075","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.chroma.2012.05.028","article-title":"A sensitive and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclastasvir) in human plasma and urine","volume":"1245","author":"Jiang","year":"2012","journal-title":"J. Chromatogr. A"},{"issue":"2","key":"10.1016\/j.jpba.2019.03.065_bib0080","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1039\/C6RA25826C","article-title":"Electrochemical design of a new nanosensor based on cobalt nanoparticles, chitosan and MWCNT for the determination of daclatasvir: a hepatitis C antiviral drug","volume":"7","author":"Azab","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.jpba.2019.03.065_bib0085","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jpba.2018.01.038","article-title":"Ultrasensitive spectrofluorimetric method for rapid determination of daclatasvir and ledipasvir in human plasma and pharmaceutical formulations","volume":"152","author":"Abo-Zeid","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.03.065_bib0090","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.saa.2018.07.101","article-title":"Micellar spectrofluorimetric protocol for the innovative determination of HCV antiviral (daclatasvir) with enhanced sensitivity: application to human plasma and stability study","volume":"206","author":"Abdel-Lateef","year":"2019","journal-title":"Spectrochim. Acta Part A"},{"key":"10.1016\/j.jpba.2019.03.065_bib0095","doi-asserted-by":"crossref","first-page":"61","DOI":"10.22159\/ajpcr.2016.v9s3.14616","article-title":"Method development and validation of ultraviolet-visible spectroscopic method for the estimation of Hepatitis-c drugs - daclatasvir and sofosbuvir in active pharmaceutical ingredient form","volume":"9","author":"Ashok Chakravarthy","year":"2016","journal-title":"Asian J. Pharm. Clin. Res."},{"key":"10.1016\/j.jpba.2019.03.065_bib0100","doi-asserted-by":"crossref","first-page":"28","DOI":"10.26502\/jppr.0004","article-title":"The development of a new validated HPLC and spectrophotometric methods for the simultaneous determination of daclatasvir and sofosbuvir: antiviral drugs","volume":"1","author":"Eldin","year":"2017","journal-title":"J. Pharm. Pharmacol. Res."},{"key":"10.1016\/j.jpba.2019.03.065_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7897\/2230-8407.079104","article-title":"UV spectrophotometric method for estimation of new drug, daclatasvir dihydrochloride","volume":"7","author":"Jeevana Jyothi","year":"2016","journal-title":"Int. Res. J. Pharm."},{"issue":"8","key":"10.1016\/j.jpba.2019.03.065_bib0110","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/bio.3551","article-title":"Two validated spectrofluorimeteric and high performance liquid chromatography (HPLC) methods with fluorescence detection for the analysis of a new anti-hepatitis C drug, daclatasvir hydrochloride, in raw material or tablet form and in biological fluids","volume":"33","author":"Aboshabana","year":"2018","journal-title":"Luminescence"},{"issue":"6","key":"10.1016\/j.jpba.2019.03.065_bib0115","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/bio.3514","article-title":"Pharmacokinetic evaluation of daclatasvir and ledipasvir in healthy volunteers using a validated highly sensitive spectrofluorimetric method","volume":"33","author":"Abdallah","year":"2018","journal-title":"Luminescence"},{"issue":"2","key":"10.1016\/j.jpba.2019.03.065_bib0120","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1570-0232(02)00914-5","article-title":"Optimization of protein precipitation based upon effectiveness of protein removal and ionization effect in liquid chromatography-tandem mass spectrometry","volume":"785","author":"Polson","year":"2003","journal-title":"J. Chromatogr. B"},{"issue":"16","key":"10.1016\/j.jpba.2019.03.065_bib0125","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1002\/jssc.200500185","article-title":"Separation and characterization of antioxidants from Spirulina platensis microalga combining pressurized liquid extraction, TLC, and HPLC-DAD","volume":"28","author":"Jaime","year":"2005","journal-title":"J. Sep. Sci."},{"issue":"1\u20132","key":"10.1016\/j.jpba.2019.03.065_bib0130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0021-9673(99)00832-8","article-title":"Solid-phase extraction: method development, sorbents, and coupling with liquid chromatography","volume":"856","author":"Hennion","year":"1999","journal-title":"J. Chromatogr. A"},{"issue":"1","key":"10.1016\/j.jpba.2019.03.065_bib0135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jpha.2011.10.005","article-title":"Spectrofluorimetric method for determination of some angiotensin II receptor antagonists","volume":"2","author":"El-Shaboury","year":"2012","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jpba.2019.03.065_bib0140","unstructured":"Guidelines, I. https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Quality\/Q2_R1\/Step4\/Q2_R1__Guideline.pdf."},{"issue":"Suppl. 1","key":"10.1016\/j.jpba.2019.03.065_bib0145","first-page":"S49","article-title":"Limit of blank, limit of detection and limit of quantitation","volume":"29","author":"Armbruster","year":"2008","journal-title":"Clin. Biochem. Rev."},{"issue":"8","key":"10.1016\/j.jpba.2019.03.065_bib0150","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s40262-017-0624-3","article-title":"Daclatasvir: a review of preclinical and clinical pharmacokinetics","volume":"57","author":"Gandhi","year":"2018","journal-title":"Clin. Pharmacokinet."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708518329236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708518329236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T00:33:14Z","timestamp":1574469194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708518329236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":30,"alternative-id":["S0731708518329236"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2019.03.065","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A clinical study for the evaluation of pharmacokinetic interaction between daclatasvir and fluoxetine","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2019.03.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}